arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Aclaris Therapeutics, Inc.

ACRS
$5.25 ▼ -0.47 (-8.21%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
51 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

Aclaris Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $749.4M
Dividend Yield
Revenue Growth -8.3%
Op. Margin None
ROIC -15.4%
FCF / Share $-0.14
Trailing P/E
Price / Book 5.9x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.63M
↓ -8.3%
Net Income Profit after all expenses
$-19.82M
↓ -31.4%
Operating Margin Operating profit as % of sales
-240.9%
↑ +48.2%
FCF / Share Free cash flow per share
$-0.14
↑ +1.1%
Long-Term Debt Long-term obligations
$10.73M
— +0.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
14
Cash Quality
50

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 14 years · 51 quarters